Clover Health is showing solid membership and revenue growth, achieving GAAP profitability with improved economics and operating leverage. The company raised its 2026 guidance and maintains a 5-star PPO rating, positioning it well against peers. Despite rapid EBITDA growth, its valuation remains attractive, trading at a discount to sector averages. Key risks include regulatory changes, claims inflation, and scaling its software business, Counterpart Health, to justify higher multiples.
Clover Health Investments Corp. (CLOV) trades at USD 4.46 on Pluang as of Nov 06, 2026 20:31 WIB, slightly down 0.33% for the day. The stock's market cap stands at $2.38 billion with a 52-week range between $1.70 and $5.41. This pricing context highlights the company's ongoing growth story and valuation dynamics mentioned in the news.
